Viatris is a healthcare company. Co.'s portfolio comprises of approved molecules across a range of therapeutic areas, including brands, generic, complex generic and biosimilars. From cardiovascular health to oncology, Co. provides treatment options across therapeutic areas covering a variety of non-communicable and infectious diseases. Co. also provides support services such as diagnostic clinics, educational seminars and digital tools. Co. provides a range of treatment options across all its therapeutic areas, with several categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for optimal treatment. More details about Viatris at:
http://www.viatris.com.
ETFs holding VTRS »
Should Viatris shares be counted among the
Top 10 Cheap Undervalued Stocks? To start, we see that the recent trading price for VTRS stock is $11.10 (as of 4/17/2024). The most recent quarter's (MRQ) earnings result, annualized, was $2.48/share. Looking at the sum total of quarterly earnings across the trailing twelve month (TTM) period, Viatris produced $2.93/share. And taking the median quarterly result across the TTM period, and annualizing it, results in $3.04/share. Comparing these various earnings metrics against the stock price, we end up with a PE ratio of 3.7 for the TTM Median method, 4.5 for price to earnings using MRQ annualized, and 3.8 for current price/TTM earnings. Based on VTRS's history, that recent TTM PE is elevated relative to the historical average, with the recent PE 2.7% higher than the average (TTM method) of 3.7.